Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Abstract Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, imp...

Full description

Bibliographic Details
Main Authors: Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortés
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00439-5

Internet

https://doi.org/10.1038/s41523-022-00439-5

Similar Items